RZLT

NASDAQ open

Rezolute

3.94 USD
▼-0.27-6.31%
盘后 3.60 0.00%
2026-11-20
市值
$411.22M
市盈率
—
EPS
-0.75
股息率
—
52 周区间
1.07 – 11.17
成交量
1.46M
Beta
0.62
目标价
10.80
52W 低 1.0752W 高 11.17
价格走势

公司简介

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquar...